Obsidian Therapeutics, Inc. has granted stock options to its Chief Financial Officer, Julie B. Feder, as part of its strategy to incentivize leadership within the company. This move underscores the importance of aligning executive compensation with company performance, particularly in the competitive pharmaceutical preparations industry.
Background
Obsidian Therapeutics, Inc. operates within the pharmaceutical preparations sector (SIC 2834) and is listed on the Nasdaq under the ticker symbol OBX. The company is classified as a smaller reporting company and an emerging growth company. Recent filings include multiple Form 4 submissions, indicating ongoing activity in executive compensation and ownership changes.
What the Filing Says
The recent filing, dated November 13, 2026, reveals that Feder was granted stock options to purchase 164,790 shares of common stock at an exercise price of $12 per share. The options were granted on August 3, 2026, and will vest in sixteen equal quarterly installments, starting on January 12, 2027. This structure is designed to ensure that Feder remains with the company while also benefiting from its long-term success.
Impact
This stock option grant may affect the company's executive retention strategy and overall performance. By tying compensation to stock performance, Obsidian Therapeutics aims to motivate its leadership to drive growth and innovation. The pharmaceutical preparations industry often sees such practices as a way to attract and retain top talent, which is crucial for maintaining a competitive edge.
What's Next
The filing does not say what happens next.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust



